Mikihiro Nakayama

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Kohjiro Ueki, Takayoshi Sasako, Yukiko Okazaki et al. · The Lancet Diabetes & Endocrinology · 2017 · 309 citations

Medicine, Cardiology, Internal Medicine +13

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

Peter Rossing, Stefan D. Anker, Gerasimos Filippatos et al. · Diabetes Care · 2022 · 199 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy

Shigehiro Katayama, Daishiro Yamada, Mikihiro Nakayama et al. · Journal of Diabetes and its Complications · 2016 · 128 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 122 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Aldose Reductase Inhibition Prevents Glucose-induced Apoptosis in Cultured Bovine Retinal Microvascular Pericytes

Keiji Naruse, Jun Nakamura, Yuichi Hamada et al. · Experimental Eye Research · 2000 · 95 citations

Life Sciences, Biochemistry, Cell Biology +10